Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2024-09-01 Epub Date: 2024-07-20 DOI:10.1007/s11886-024-02097-4

Jennifer M Kaplan, Adnin Zaman, Layla A Abushamat

{"title":"Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?","authors":"Jennifer M Kaplan, Adnin Zaman, Layla A Abushamat","doi":"10.1007/s11886-024-02097-4","DOIUrl":null,"url":null,"abstract":"Purpose of review: This article summarizes the medical management of obesity with an emphasis on incretin-based therapeutics that target the neuro-hormonal basis of obesity.Recent findings: Medications that mimic the effect of incretins, a group of peptide hormones released in response to nutrient intake that regulate appetite, result in potent and durable weight loss. Glucagon-like peptide 1 (GLP-1) agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists such as semaglutide and tirzepatide are approved by the United States Food and Drug Administration (FDA) for the management of obesity. The SELECT trial demonstrated that semaglutide led to a reduction in major adverse cardiovascular events in patients without diabetes who were either overweight and had preexisting cardiovascular disease or obese.Summary: The treatment of obesity is critical to prevent the progression of cardiovascular-kidney-metabolic syndrome. Incretin-based therapies offer remarkable weight loss and reduce major cardiovascular adverse events.","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11886-024-02097-4","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This article summarizes the medical management of obesity with an emphasis on incretin-based therapeutics that target the neuro-hormonal basis of obesity.

Recent findings: Medications that mimic the effect of incretins, a group of peptide hormones released in response to nutrient intake that regulate appetite, result in potent and durable weight loss. Glucagon-like peptide 1 (GLP-1) agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists such as semaglutide and tirzepatide are approved by the United States Food and Drug Administration (FDA) for the management of obesity. The SELECT trial demonstrated that semaglutide led to a reduction in major adverse cardiovascular events in patients without diabetes who were either overweight and had preexisting cardiovascular disease or obese.

Summary: The treatment of obesity is critical to prevent the progression of cardiovascular-kidney-metabolic syndrome. Incretin-based therapies offer remarkable weight loss and reduce major cardiovascular adverse events.

Abstract Image

查看原文本刊更多论文

遏制肥胖症流行：GLP-1 受体激动剂是否应成为治疗肥胖症的标准药物？

综述目的：本文总结了肥胖症的医学治疗方法，重点介绍了针对肥胖症神经激素基础的增量素疗法：最近的研究结果：模仿增量素作用的药物能有效、持久地减轻体重，增量素是一组随营养摄入而释放的肽类激素，能调节食欲。胰高血糖素样肽1（GLP-1）激动剂和葡萄糖依赖性促胰岛素多肽（GIP）激动剂，如 semaglutide 和 tirzepatide，已被美国食品和药物管理局（FDA）批准用于治疗肥胖症。SELECT 试验表明，对于体重超重并已患有心血管疾病或肥胖的无糖尿病患者，semaglutide 可减少主要不良心血管事件的发生。摘要：肥胖症的治疗对于预防心血管-肾脏-代谢综合征的恶化至关重要。基于胰岛素的疗法可显著减轻体重，减少主要心血管不良事件的发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567